Recent News

• 10.03.2025 - Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 10.03.2025 - Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 09.29.2025 - Vor Bio Announces Late-Breaking Poster Presentation of Phase 3 Primary Sjögren’s Disease Clinical Study at ACR Convergence 2025
• 09.29.2025 - Vor Bio Announces Late-Breaking Poster Presentation of Phase 3 Primary Sjögren’s Disease Clinical Study at ACR Convergence 2025
• 09.23.2025 - Vor Bio Appoints Navid Z. Khan, Ph.D., as Chief Medical Affairs Officer
• 09.23.2025 - Vor Bio Appoints Navid Z. Khan, Ph.D., as Chief Medical Affairs Officer
• 09.17.2025 - Vor Bio Announces Oral Presentation of 48-Week China Phase 3 Generalized Myasthenia Gravis Clinical Study at AANEM
• 09.17.2025 - Vor Bio Announces Oral Presentation of 48-Week China Phase 3 Generalized Myasthenia Gravis Clinical Study at AANEM
• 09.15.2025 - Stifel 2025 Virtual Immunology and Inflammation Forum

Recent Filings

• 10.03.2025 - 4 Statement of changes in beneficial ownership of securities
• 09.26.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 09.25.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 09.24.2025 - S-3 Registration statement under Securities Act of 1933
• 09.24.2025 - S-8 Securities to be offered to employees in employee benefit plans
• 09.23.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 09.22.2025 - 4 Statement of changes in beneficial ownership of securities
• 09.19.2025 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
• 09.18.2025 - 4 Statement of changes in beneficial ownership of securities
• 09.17.2025 - 8-K Current report